- Litigation / Dispute Resolution (22)
- Healthcare (20)
- Intellectual Property (19)
- Company/Commercial (17)
- Corporate (16)
- Banking / Finance (9)
- Information Technology (9)
- Regulatory and compliance (9)
- Employment (6)
- Clinical/Medical Negligence (5)
- Real Estate (5)
- Commodities (4)
- Competition/EU (4)
- Energy (4)
- Crime (3)
- Financial services (3)
- Insurance/reinsurance (3)
- Media/Entertainment/Sport (3)
- Tax (3)
- Transport (Including aviation and shipping) (3)
- Environment (2)
- Funds (2)
- Privacy and reputation (2)
- Private Equity (2)
- Telecoms (2)
- Agriculture (1)
- Licensing/Gaming/Betting (1)
- Pensions (1)
- Personal tax / Trusts (1)
- Planning (1)
- Public Sector/Local Authority (1)
Sort By: Newest first | Oldest first
DLA Piper’s ‘Life sciences: patent extension strategies and antitrust global update’ video covers global antitrust and competition issues including product hopping and reverse payment patents.
Health Alert — Julia Clare v Australian Community Pharmacy Authority; Dr Reid v Medical Council of NSW; and more
DLA Piper has released the 22 December 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The European Court of Justice (CJEU) has handed down a landmark judgment concerning the patentability of stem cells in Europe.
Patents directed to genetic material have been the subject of significant public discourse and legal challenge worldwide.
The Supreme Court ruled in FTC v Actavis that settlement agreements for patent infringement suits between branded and generic drug companies are not immune from antitrust scrutiny.
DLA Piper has advised Pfizer on the $635m (£405m) acquisition of commercial vaccines from Baxter.
DLA Piper has acted for China’s largest pharmaceutical company on the issuance of HK$5.5bn of new shares.
DLA Piper has advised Australian Securities Exchange-listed REVA Medical Inc on the issue of $25m (£15.8m) of convertible notes and also 8,750,000 options to an international investor consortium.
DLA Piper advised Neothetics in the pricing of its initial public offering of 4,650,000 shares of its common stock at a public offering price of $14 per share.
DLA Piper and Gallastegui Lozano are to combine in Mexico City. Locally, the combined firm will adopt the name DLA Piper Gallastegui y Lozano.
Health Alert — Gray v Richards; Psychology Board of Australia v G; health insurance legislation amendment; and more
DLA Piper has released the 20 October 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has advised Synergy Health on its recommended combination with STERIS Corporation.
This guide provides sound, practical advice on the relevant laws and regulations for foreign companies looking to invest in Australia.
DLA Piper has recruited Mark Riera as a litigation partner in its Los Angeles office. Riera is a trial and appellate lawyer with experience in a range of industries.
In D’Arcy v Myriad Genetics, five judges of the Full Federal Court of Australia have confirmed that isolated nucleic acid sequences are patentable subject matter in Australia.
Debates on the laws and regulations that will govern biosimilar products have been raging for some time.
Intellectual Property and Technology News — state biosimilars laws are evolving; surviving a trademark opposition challenge; and more
DLA Piper has released issue 23 of its Intellectual Property and Technology News, which reports on worldwide developments in IP and technology law.
Life Sciences Spotlight: Chinese regulatory enforcement action not slowing down; patent strategies and loyalty discounts; and more
DLA Piper has released the fourth edition of Life Sciences Spotlight, which discusses developments in the sector across the Asia-Pacific region.
Life Sciences Spotlight: Chinese regulatory enforcement action showing no signs of slowing down; and more
Welcome to the fourth edition of Life Sciences Spotlight.
European Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine
The European Commission has imposed fines totalling €427.7m on the French pharmaceutical company Servier and five producers of generic medicines.